Medicinal Mushroom - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The medicinal mushroom market size is projected to expand from USD 7.87 billion in 2025 and USD 8.48 billion in 2026 to USD 12.79 billion by 2031, registering a CAGR of 8.56% between 2026 to 2031. This report is Segmented by Type (Reishi, Chaga, Cordyceps, Lion's Mane, Others), Form (Extracts, Powder, Capsules and Tablets, Others), Function (Immune Support, Cognitive Support, Anti-Cancer, Others), Distribution Channel (Online Retail, Supermarkets, Pharmacies, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Medicinal Mushroom Market Trends and Insights

Rising Consumer Demand for Natural Immune Resilience

Consumer demand for proactive immune support has remained well above pre-2020 levels, and that sustained behavior continues to anchor the medicinal mushroom market. Reishi and Turkey Tail stay central to this demand because both species are already tied to established immune positioning in supplements and wellness blends. A 2025 randomized, double-blind, placebo-controlled study tied to Fungi Perfecti and UC San Diego reported measurable immune-balancing effects from Lion’s Mane mushroom mycelium under stress conditions, which gave brands a stronger scientific base for targeted immune messaging. That shift is important because it moves product positioning away from broad wellness language and toward more specific, evidence-based communication that can justify higher prices and better placement. In the medicinal mushroom market, companies with stronger study files are in a better position to protect claims, support retailer discussions, and hold premium margins as buyers become more selective. This pattern also raises pressure on smaller brands that rely on generic immune narratives without clear product differentiation or documented active content.

Expansion of Nootropic and Cognitive Wellness Use

Cognitive wellness is becoming one of the strongest demand engines in the medicinal mushroom market, with Lion’s Mane at the center of that shift. A double-blind, randomized, placebo-controlled crossover study published in Frontiers in Nutrition in April 2025 found that a 3 g standardized Hericium erinaceus fruiting body extract improved psychomotor skill performance in healthy adults, even though the effects were not universal across all cognition tasks. That matters because it supports more precise positioning around reaction speed, dexterity, and stress-related performance rather than broad claims that every aspect of cognition will improve. The clinical base is also widening because additional randomized studies were registered in 2025 and early 2026 to compare Lion’s Mane extract formats and track cognitive, biomarker, and gut microbiota outcomes. As these trials progress, the medicinal mushroom market is likely to see a clearer separation between premium formulators that can support narrow function claims and brands that still sell on general nootropic appeal. This supports product segmentation by extract type, formulation method, and target use rather than by species name alone.

Regulatory Inconsistency and Claims Substantiation Burden

Regulatory complexity remains one of the clearest friction points in the medicinal mushroom market because product language, ingredient status, and launch timelines differ sharply across regions. In the United States, structure and function wording can be used under dietary supplement rules, but disease claims are not allowed, which creates a narrow path for consumer communication. The FDA reinforced that boundary when it issued a warning letter in September 2025 tied to adulterated Amanita muscaria products after its earlier determination that Amanita muscaria does not meet GRAS standards. In Europe, novel food authorization can slow launches for certain mushroom extracts and add material cost, which is especially difficult for smaller entrants with limited regulatory budgets. The medicinal mushroom market therefore operates through a patchwork of compliance expectations that raises formulation, legal, and packaging costs without creating a simple global playbook. That uncertainty often pushes brands toward safer but less differentiated claim language, which can weaken shelf impact and slow category development.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Clean-Label Plant-Based Supplements and Functional Foods
• Clinical Validation and Standardized Extract Adoption
• Raw Material Contamination and Adulteration Risk

Segment Analysis

Reishi held 24.32% of type-segment revenue in 2025, while Lion’s Mane is forecast to expand at a 9.39% CAGR through 2031, showing that the medicinal mushroom market is balancing established demand with newer growth stories. Reishi’s lead reflects its long integration into traditional Chinese and Japanese use patterns and its broad positioning across immune, anti-fatigue, and stress-related applications. Lion’s Mane is building momentum because the evidence base around cognition, mood, and function-specific outcomes is widening, which gives brands more room to develop targeted products. A 2025 systematic review in Frontiers in Nutrition brought together 5 randomized controlled trials on Hericium erinaceus and found measurable benefits across mild cognitive impairment, depression, and menopause-related symptoms. In the medicinal mushroom market, that body of evidence is helping Lion’s Mane move from a single-product hero ingredient into a platform for differentiated cognitive and emotional wellness positioning.

Cordyceps and the other medicinal mushroom types retained smaller shares of the medicinal mushroom market, but they continue to build credible demand in narrower use cases. Turkey Tail benefits from its long-standing connection to oncology-adjacent wellness, while Shiitake gains from consumer familiarity as both a food ingredient and a wellness ingredient. Cordyceps militaris also has clinical support from a randomized controlled trial that examined immune response in healthy adults, which helps the segment maintain relevance outside endurance and energy narratives. Provenance is becoming more important across this segment because buyers increasingly distinguish between commodity-grade supply and traceable premium material with clearer cultivation documentation. This shift favors producers that can show origin, identity, and processing transparency, especially when the medicinal mushroom industry is trying to defend premium pricing against lower-cost, less-verified supply.

Extracts accounted for 38.23% of revenue in 2025, which shows that concentration, convenience, and perceived potency remain central buying criteria in the medicinal mushroom market size for form-level products. Their lead also reflects the fact that extracts fit both direct-consumer supplement formats and ingredient supply into powders, beverages, blends, and other functional food applications. Competitive differentiation inside extracts increasingly depends on whether brands can explain water, ethanol, or dual-extraction methods in a credible way and connect those methods to active content. Standardized beta-glucan messaging and third-party testing matter more here than in lower-processed forms because buyers expect extracts to offer measurable value beyond raw mushroom material. Dried mushrooms, fresh mushrooms, powders, teas, and tinctures still play an important role because they serve traditional-use consumers, culinary wellness formats, and shoppers who prefer less processed presentations.

Capsules and Tablets are projected to grow at an 8.76% CAGR through 2031, making them the fastest-growing form because they simplify dosing and fit everyday supplement routines. That growth also reflects wider acceptance among office workers and older adults who prefer familiar delivery forms with straightforward label directions. In March 2026, Host Defense launched a mushroom gummy line, which shows how format expansion is being used to draw in new consumers who care more about taste and consistency than extract strength per serving. Liquid extracts are also gaining attention in some European markets because fast-absorption positioning and traditional-use cues still resonate with specialist buyers. Across the medicinal mushroom market, form choice is now part of category strategy rather than simple packaging, since it shapes compliance, consumer entry, repeat use, and price realization.

Complete Report Scope:

• By Type
  • Reishi
  • Chaga
  • Cordyceps
  • Lion’s Mane
  • Turkey Tail
  • Maitake
  • Shiitake
  • Other Medicinal Mushroom Types
• By Form
  • Fresh Mushrooms
  • Dried Mushrooms
  • Extracts
  • Powder
  • Capsules and Tablets
  • Liquid Extracts
  • Teas and Tinctures
• By Function
  • Immune Support
  • Cognitive Support
  • Anti-Cancer Support
  • Antioxidant Support
  • Skin Care Support
  • Stress and Sleep Support
  • Other Functional Applications
• By Distribution Channel
  • Online Retail
  • Supermarkets and Hypermarkets
  • Pharmacies and Drugstores
  • Specialty Stores
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific held 38.63% of global revenue in 2025, which made it the largest regional block in the medicinal mushroom market and reflected its strong cultivation base, processing depth, and longstanding cultural familiarity with medicinal fungi. China remains central because it carries major cultivation and extraction capacity for several commercially important species. Japan also matters because Reishi and Lion’s Mane already fit into established wellness and traditional-use frameworks, which supports both specialist and mainstream product circulation. South Korea is building relevance through functional food and cosmetics applications that use mushroom bioactives in beverages, snacks, and skin-related products. Published Lion’s Mane trials have also included Japanese study populations, which reinforces the region’s influence on the evidence base behind cognition-focused products.

North America is projected to grow at a 9.04% CAGR through 2031, making it the fastest-growing geography in the medicinal mushroom market. The region’s strength comes from advanced e-commerce infrastructure, active direct-to-consumer brands, and a consumer base that is comfortable experimenting with new supplement formats. The United States remains the main engine because digital education, subscription programs, and product storytelling are especially effective in categories that require explanation around sourcing and active content. Canada adds support through a relatively developed natural health product environment, while Mexico represents an earlier-stage opportunity where modern supplement distribution is still building. Europe remains important but more complex because retail buyers often expect stronger product dossiers, clearer ingredient documentation, and more conservative health positioning than many North American brands are used to providing.

Middle East and Africa and South America are the smallest geographies in the medicinal mushroom market, and both regions still rely heavily on imported products because local cultivation and extraction depth remain limited for premium species. In the Gulf markets, especially the UAE and Saudi Arabia, interest is strongest among urban consumers who already spend on premium wellness and functional food products. South Africa remains a smaller but visible entry point because specialty retail and imported wellness categories are becoming easier to access. In South America, Brazil and Argentina are the primary markets, and cross-border e-commerce is the most immediate route for wider category penetration because it allows global brands to reach consumers even where local specialist distribution is still thin.

List of Companies Covered in this Report:

• Aloha Medicinals, Inc.
• Banken Champignons B.V.
• Far West Fungi
• Four Sigmatic Foods Inc.
• FreshCap Mushrooms
• Fungi Perfecti LLC
• Gaia Herbs Inc.
• Hifas da Terra
• Hokkaido Reishi Co., Ltd.
• Host Defense Mushrooms
• Life Cykel Pty Ltd
• Mushroom Science
• Nammex
• Nature’s Way Brands LLC
• Om Mushroom Superfood
• Oriveda B.V.
• Real Mushrooms
• Swanson Health Products, Inc.
• Wakunaga Pharmaceutical Co., Ltd.
• Xian Greena Biotech Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support